Two private companies in the healthcare sector, Penumbra Inc. and RegenXBio Inc., are planning on going public in later this week. Both companies have set terms in their filings with the U.S. Securities and Exchange Commission (SEC) for respective initial public offerings (IPO). Penumbra plans to list on the New York Stock Exchange (NYSE) under the symbol PEN, while RegenXBio intends to list on the NASDAQ Global Market under the symbol RGNX.

First of all, Penumbra expects the offering to price to fall in a range between $25 and $28 for 3.8 million shares, with an overallotment option for an additional 570,000 shares. The total offering at the maximum price is valued up to $122.36 million. The underwriters for the offering are JPMorgan, Merrill Lynch, Wells Fargo and Canaccord Genuity.

This global interventional therapies company designs, develops, manufactures and markets innovative medical devices. Penumbra has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. The conditions that these products address include ischemic and hemorrhagic stroke, which involve blockage or rupture of blood vessels in the brain, and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures, which involve the use of medical devices to remove or treat blockages or ruptures of blood vessels.

When it was founded in 2004, the company was originally focused on the neuro market, but it recently expanded its business into the peripheral vascular market.

RegenXBio set the terms in its offering in an expected price range of $17 to $19 for approximately 5.556 million shares. At the maximum price, the total offering is valued up to $121.39 million. The underwriters for the offering are Morgan Stanley, Merrill Lynch, Piper Jaffray, and Chardan Capital Markets.

This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The proprietary AAV gene delivery platform consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

The company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, based on its NAV Technology Platform. It seeks to accomplish its mission through a combination of internal development efforts and the efforts of third-party licensees.

ALSO READ: The Least Healthy City in Every State

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.